4519.T Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 09:15):

Stats
Šios dienos apimtis	4.61M
Vidutinė apimtis	2.54M
Rinkos kapitalizacija	7 983.40B
EPS	¥45.22 ( 2024-04-24 )
Kita pelno data	( ¥52.88 ) 2024-07-25
Last Dividend	¥40.00 ( 2023-06-29 )
Next Dividend	¥0 ( N/A )
P/E	24.45
ATR14	¥4.69 (0.10%)

Tūris Koreliacija

Ilgas: -0.43 (neutral)

Trumpas: -0.81 (strong negative)

Signal:(28.37) Be Aware. Possible trading coming up! (swing)

Chugai Pharmaceutical Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Chugai Pharmaceutical Koreliacija - Valiuta/Žaliavos

-0.07
( neutral )

-0.08
( neutral )

0.03
( neutral )

-0.17
( neutral )

0.34
( neutral )

0.38
( neutral )

Chugai Pharmaceutical Finansinės ataskaitos

Annual	2023
Pajamos:	¥1 111.37B
Bruto pelnas:	¥693.01B (62.36 %)
EPS:	¥197.83

FY	2023
Pajamos:	¥1 111.37B
Bruto pelnas:	¥693.01B (62.36 %)
EPS:	¥197.83

FY	2022
Pajamos:	¥1 259.95B
Bruto pelnas:	¥783.70B (62.20 %)
EPS:	¥227.64

FY	2021
Pajamos:	¥999.76B
Bruto pelnas:	¥661.61B (66.18 %)
EPS:	¥184.37

Financial Reports:

No articles found.

Chugai Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥0 (N/A)	¥40.00 (N/A)	¥0 (N/A)	¥40.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Chugai Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 8.15 - good (81.48%) | Divividend Growth Potential Score: 5.92 - Stable (18.36%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥0.500	2000-03-28
Last Dividend	¥40.00	2023-06-29
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	48	--
Total Paid Out	¥538.17	--
Avg. Dividend % Per Year	0.00%	--
Score	3.59	--
Div. Sustainability Score	8.15
Div.Growth Potential Score	5.92
Div. Directional Score	7.03	--

Next Divdend (Est)
(2024-10-10)

¥0 Estimate 3.74 %

Dividend Stability

0.30 Very Poor

Dividend Score

3.59

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
9531.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
8174.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7552.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6762.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6101.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
4812.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
4026.T	Ex Dividend Knight	2023-10-30	Semi-Annually	0.00%
3242.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
2267.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
9042.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.315	1.500	3.70	5.55	[0 - 0.5]
returnOnAssetsTTM	0.172	1.200	4.27	5.12	[0 - 0.3]
returnOnEquityTTM	0.207	1.500	8.81	10.00	[0.1 - 1]
payoutRatioTTM	0.402	-1.000	5.98	-5.98	[0 - 1]
currentRatioTTM	5.53	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.21	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.937	1.500	0.351	0.526	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	18 133	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	233.57	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	197.34	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.677	1.000	2.05	2.05	[0.2 - 0.8]
operatingProfitMarginTTM	0.420	1.000	3.60	3.60	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.546	0.800	9.69	7.75	[0.5 - 2]
Total Score				8.15

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	24.46	1.000	7.63	0	[1 - 100]
returnOnEquityTTM	0.207	2.50	9.24	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	197.34	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	1.649	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	233.57	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.402	1.500	5.98	-5.98	[0 - 1]
pegRatioTTM	0.435	1.500	-0.430	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.371	1.000	3.23	0	[0.1 - 0.5]
Total Score				5.92

Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.